Drug Trial Radar · NCT05500482
Vellore Typhoid Vaccine Impact Trial
Last checked: Nov 19, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72,400
Actual
Start
May 1, 2023
Primary completion
Jan 31, 2026
Study completion Feb 28, 2026
Sponsor
- Lead sponsor
- Christian Medical College, Vellore, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; University College, London; Imperial College London
- First posted
- Aug 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
Conditions
- Typhoid Fever
Interventions
Typhoid conjugate VaccineBiological
TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total effectTime frame: at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Christian Medical College Vellore
Vellore, Tamil Nadu, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.